Cisplatin and cranial irradiation-related hearing loss in children

Ochsner Journal

Volumn 12, Issue 3, 2012, Pages 191-196

  Warrier, Rajasekharan ^a   Chauhan, Aman ^b   Davluri, Murali ^c   Tedesco, Sonya L ^d   Nadell, Joseph ^d   Craver, Randall ^e  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c Children's Hospital ^*

^d CHILDREN S HOSPITAL   (United States)

^e LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cisplatin; Cranial irradiation; Ototoxicity; Pediatric brain tumor

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; MANNITOL; VINCRISTINE;

ADOLESCENT; AGE DISTRIBUTION; ANALYSIS OF VARIANCE; ARTICLE; ASTROCYTOMA; AUDITORY THRESHOLD; BRAIN TUMOR; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DIURESIS; DRUG EFFICACY; DRUG SAFETY; DYSGERMINOMA; EPENDYMOMA; FEMALE; HEARING LOSS; HUMAN; HYDRATION; INCIDENCE; INFANT; MALE; MEDULLOBLASTOMA; NEUROBLASTOMA; NEUROECTODERM TUMOR; OSTEOSARCOMA; OTOTOXICITY; PATIENT MONITORING; PINEAL BODY TUMOR; POPULATION RESEARCH; PRESCHOOL CHILD; RHABDOMYOSARCOMA; SCHOOL CHILD; SEX DIFFERENCE; SKULL IRRADIATION; TREATMENT RESPONSE;

EID: 84866516518     PISSN: 15245012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Rosenberg B, Van Camp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature. 1965 Feb 13;205:698-699.
2. Packer RJ, Sutton LN, Elterman R, et al. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg. 1994 Nov;81(5):690-698
3. Rosen EM, Cassady JR, Frantz CN, Kretschmar C, Levey R, Sallan SE. Neuroblastoma: the Joint Center for Radiation Therapy/Dana-Farber Cancer Institute/Children's Hospital experience. J Clin Oncol. 1984 Jul;2(7):719-732.
4. Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys. 1979 Jan;5(1):85-91.
5. McHaney VA, Thibadoux G, Hayes FA, Green AA. Hearing loss in children receiving cisplatin chemotherapy. J Pediatr. 1983 Feb; 102(2):314-317.
6. Weatherly RA, Owens JJ, Catlin FI, Mahoney DH. Cis-platinum ototoxicity in children. Laryngoscope. 1991 Sep;101(9):917-924
7. Walker DA, Pillow J, Waters KD, Keir E. Enhanced cis-platinum ototoxicity in children with brain tumours who have received simultaneous or prior cranial irradiation. Med Pediatr Oncol. 1989;17(1):48-52.
8. Grau C, Mller K, Overgaard M, Overgaard J, Elbrnd O. Sensorineural hearing loss in patients treated with irradiation for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1991 Aug;21(3):723-728.
9. Schell MJ, McHaney VA, Green AA, et al. Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. J Clin Oncol. 1989 Jun;7(6):754-760.
10. Kretschmar CS, Warren MP, Lavally BL, Dyer S, Tarbell NJ. Ototoxicity of preradiation cisplatin for children with central nervous system tumors. J Clin Oncol. 1990 Jul;8(7):1191-1198.
11. Cohen BH, Zweidler P, Goldwein JW, Molloy J, Packer RJ. Ototoxic effect of cisplatin in children with brain tumors. Pediatr Neurosurg. 1990-1991;16(6):292-296.
12. Khan AB, D'Souza BJ, Wharam MD, et al. Cisplatin therapy in recurrent childhood brain tumors. Cancer Treat Rep. 1982 Dec; 66(12):2013-2020.
13. Sexauer CL, Khan A, Burger PC, et al. Cisplatin in recurrent pediatric brain tumors. A POG Phase II study. A Pediatric Oncology Group Study. Cancer. 1985 Oct 1;56(7):1497-1501.
14. Walker RW, Allen JC. Treatment of recurrent primary intracranial childhood tumors with cis-diamminedichloroplatinum. Ann Neurol. 1983 Sep;14(3):371-372.
15. Granowetter L, Rosenstock JG, Packer RJ. Enhanced cisplatinum neurotoxicity in pediatric patients with brain tumors. J Neurooncol. 1983;1(4):293-297.
16. Sweetow RW, Will TI. Progression of hearing loss following the completion of chemotherapy and radiation therapy: case report. J Am Acad Audiol. 1993 Nov;4(6):360-363.
17. Schot LJ, Hilgers FJ, Keus RB, Schouwenburg PF, Dreschler WA. Late effects of radiotherapy on hearing. Eur Arch Otorhinolaryngol. 1992;249(6):305-308.
18. Mahoney DH Jr, Weaver T, Steuber CP, Starling KA. Ototoxicity with cisplatin therapy. J Pediatr. 1983 Dec;103(6):1006-1007.
19. Rubin P. The Franz Buschke lecture: late effects of chemotherapy and radiation therapy: a new hypothesis. Int J Radiat Oncol Biol Phys. 1984 Jan;10(1):5-34.
20. Heideman RL, Kovnar EH, Kellie SJ, et al. Preirradiation chemotherapy with carboplatin and etoposide in newly diagnosed embryonal pediatric CNS tumors. J Clin Oncol. 1995 Sep;13(9): 2247-2254.
21. Gaynon PS. Carboplatin in pediatric malignancies. Semin Oncol. 1994 Oct;21(5 Suppl 12):65-76.
22. Davis H. Hearing handicap, standards for hearing and medicolegal rules. In: Davis H, Silverman SR, eds. Hearing and Deafness. 3rd ed. New York, NY: Holt, Rinehart, and Wilson; 1970.
23. Yassuda CC, Righetti AE, Cury MC, Hyppolito MA, Oliveira JA, Féres O. The role of hyperbaric oxygen therapy (hot) as an otoprotection agent against cisplatin ototoxicity. Acta Cir Bras. 2008;23 Suppl 1:72-76; discussion 76.
24. Hyppolito MA, de Oliveira AA, Lessa RM, Rossato M. Amifostine otoprotection to cisplatin ototoxicity: a guinea pig study using otoacoustic emission distortion products (DPOEA) and scanning electron microscopy [in Portuguese]. Braz J Otorhinolaryngol. 2005 May-Jun;71(3):268-273. Epub 2005 Dec 14.
25. Marina N, Chang KW, Malogolowkin M, et al; Children's Oncology Group. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study. Cancer. 2005 Aug 15;104(4):841-847.